Agoracom: Small Cap Investment - Zenith Epigenetics - New Zenith Clinical Trial Listing: ZEN003694 and Nivolumab w/ or w/o Ipilimumab in Solid Tumors

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New Zenith Clinical Trial Listing: ZEN003694 and Nivolumab w/ or w/o Ipilimumab in Solid Tumors

posted on Apr 23, 2021 08:04AM

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors. First posted April 12, 2021. Not yet recruiting.

https://clinicaltrials.gov/ct2/show/NCT04840589

This is the first of the National Cancer Institute (NCI) CRADA (Cooperative research and development agreement) studies first announced last year, in which NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate ZEN3694 with nivolumab and ipilimumab – in resistant ovarian cancers and other solid tumors.